Acid-sensing ion channels (ASICs) are a family of ion channels permeable to cations and largely responsible for the onset of acid-evoked ion currents both in neurons and in different types of cancer cells, thus representing a potential target for drug discovery. Owing to the limited attention ASIC2 has received so far, an exploratory program was initiated to identify ASIC2 inhibitors using diminazene, a known pan-ASIC inhibitor, as a chemical starting point for structural elaboration. The performed exploration enabled the identification of a novel series of ASIC2 inhibitors. In particular, compound 2u is a brain penetrant ASIC2 inhibitor endowed with an optimal pharmacokinetic profile. This compound may represent a useful tool to validate in animal models in vivo the role of ASIC2 in different neurodegenerative central nervous system pathologies.
T he variation of proton concentration in tissues is a tightly controlled process. 1 In particular, a decrease of pH has been observed both in physiological conditions, i.e., control of neuronal functions by proton-mediated signaling, and pathological conditions. 2, 3 Notably, acidification occurring in pathological conditions was found to recruit acid-sensing ion channels (ASICs), a family of proton-activated ion channels 4 that are highly expressed both in central and peripheral neurons 5 and in different types of cancer cells, 6 thus representing a potential target for drug discovery. 3, 7 ASICs are voltage-insensitive ion channels belonging to the ENaC/ DEG channel superfamily, which includes epithelial Na + channels (ENaC) and degenerins (DEG). Four ASICs genes (ASIC1−4) and two specific splice variants for ASIC1 and ASIC2 (a and b) have been described in mammals to date. ASIC1a, ASIC2a, and ASIC2b are primarily expressed in central nervous system (CNS) neurons, while all subunits are expressed in the peripheral nervous system (PNS). ASIC1a, ASIC2a, and ASIC3 subunits assemble to form both homotrimeric and heterotrimeric channels, whereas ASIC2b and ASIC4 only contribute to forming heteromeric channels with other ASIC subunits. 7, 8 In terms of electrophysiology, while ASIC1a undergoes rapid inactivation, for ASIC2 and ASIC3 a noninactivated current potentially relevant in chronic pathologies, was observed. Thus far, both ASIC1 and ASIC3 have been extensively studied, 9 while ASIC2 has received much less attention. Notably, ASIC2 has recently been proposed as a relevant target in some forms of cancer, 10, 11 whereas, in combination with ASIC1 subunits, it appears to play a key role in neuronal physiopathology. 12 Several natural peptides and synthetic small molecules, i.e., diminazene 1 (DA, Chart 1), an anti-infective veterinary drug, have been described as ASICs inhibitors. 13−15 However, the latter compound shows both poor target and ASIC isoform specificity, along with negligible blood−brain barrier (BBB) penetration, hence limiting its usage as therapeutic agent both for CNS and PNS pathologies. 16, 17 Therefore, an exploratory project was initiated, using DA as chemical starting point, to obtain brain penetrant ASIC2 inhibitors as useful tool compounds for target validation studies in CNS. To this aim, ASIC1a and ASIC2a being the most highly expressed ASIC subunits in CNS neurons, the new chemical entities (NCEs) synthesized were specifically tested for their effects on murine homotrimeric ASIC1a and ASIC2a, and on heterotrimeric ASIC1a/2a. 18 To identify the most appropriate methodology for in vitro screening of NCEs, a series of published data 19−21 on both compound 1 and amiloride, a diuretic drug known to interact with ASICs, specifically caught our attention. An optical technology based on membrane potential detection by voltagesensitive dyes (VSDs) 22−25 was proposed. This original assay format showed an adequate throughput performance, and the ability to efficiently measure the inhibitory effect of ASICstargeted NCEs. Moreover, additional evidence suggested the use of optic based assays, owing to the membrane potential sensitivity of ASIC1a binding affinity to small molecules. 20 The preliminary structural elaboration of DA, in three sequential steps, enabled the identification of 1,4-diaryl, 3−5dimethylpyrazole derivative 2a (Chart 1), an early lead compound that was fully characterized in terms of ASICs inhibition. In particular, the linear triazene linker present in DA was initially replaced by a 1,3-disubstituted five-membered heterocycle, with the aim to rigidify the molecular core. Then, to reduce the basic character of the molecule, with the aim to improve its drug-like character and possibly secure BBB permeability, one of the two amidine functions was successfully removed. Finally, an initial exploration was made on the effect of the substitution of terminal phenyl rings.
As shown in Table 1 , compound 2a exhibited greater in vitro activity than compound 1 and comparable activity on ASIC2a and ASIC1a/2a (IC 50 = 18.9 and 10.9 μM, respectively), while being inactive on ASIC1a. Based on these preliminary encouraging results, the rapid "4 points" analoging exploration strategy depicted in Chart 2 was envisioned. Namely, we focused on the sequential elaboration of the two aryl moieties ("pink and green"), the heterocycle core ("fuchsia"), and the suitable rigidification/masking of the potentially metabolically labile terminal benzyl function ("cyan").
At first, following the synthetic strategy shown in Scheme 1, nine "pink" analogues 2a−i were synthesized. In particular, pcyanophenyl boronic acid 3 was reacted with di-tert-butyl diazene 1,2-dicarboxylate and 2,4-pentanedione, to obtain 3,5dimethyl pyrazole 4. The following bromination reaction with NBS led to 4-bromo analogue 5, which was coupled with nine different aryl or heteroaryl substituted boronic acids. The resulting 1-(p-cyanophenyl) pyrazoles 6a−i were reduced to the corresponding benzylamines 2a−i with lithium aluminum hydride in moderate to good overall yields.
The inhibition of ASICs constructs by compounds 2a−i is reported in Table 1 .
Monosubstituted compounds 2c and 2d, bearing a p-CH 3 or p-OCH 3 respectively, mostly retained the activity of the pyrazole early lead compound 2a, while isoform selectivity for ASIC2a vs ASIC1a/2a was improved. Compound 2g, the m-F analogue of 2a, was the most potent and selective compound of this series. Notably, larger and/or charged functions (2e, p-CF 3 ; 2f, p-CH 2 NH 2 ), disubstituted aryls (2h, p-CH 3 , m-F) and the presence of a pyridine as phenyl replacement (2i, p-CH 3 , X = N) led to inactive compounds. 18.9 ± 6.9
a IC 50 were determined as described in the Supporting Information; they are expressed in μM and are the average value of at least n = 3 independent experiments ± SEM. Then, the influence of the 3,5-dimethyl substituents present on the pyrazole core was evaluated by synthesizing the corresponding "fuchsia" des-methyl analogue 2j (Scheme 2).
To this aim, p-cyanophenyl boronic acid 3 was treated with di-tert-butyl diazene-1,2-dicarboxylate in the presence of Cu(OAc) 2 ·H 2 O in MeOH at 65°C for 1 h, followed by cooling to room temperature and addition of 2-(4fluorophenyl)propanedial in 4 N HCl in dioxane initially at room temperature for 10 min, then at 80°C for additional 10 min to give intermediate 7 in 56% yield. Then, reduction of the cyano group led to the corresponding benzylamine 2j with lithium aluminum hydride in 73% yield.
Compound 2j was inactive in terms of ASICs inhibition (IC 50 > 30 μM on all ASICs constructs, Table 2 ), pointing out the relevance of both methyl groups for the recognition of the receptor binding site.
To acquire additional SAR information, a methylene spacer was introduced between N 1 of the pyrazole moiety ("fuchsia" compound 2k, Scheme 3) by bromination and Suzuki coupling on 3,5-dimethyl pyrazole 8, followed by alkylation at the N 1 position of 3,5-dimethyl pyrazole derivative 10a with p-CN benzyl bromide, and by final reduction of the nitrile group with lithium aluminum hydride in poor, unoptimized yields.
When compound 2k was tested for its ability to inhibit ASICs, a comparable activity and isoform selectivity was observed for ASIC2a with respect to early lead 2a ( Table 2 , IC 50 = 16.8 and 18.9 μM, respectively).
Our attention was then focused on the "cyan" exploration by moving the p-benzylamine moiety from para to meta position of the phenyl ring (compound 2l, Scheme 4), by introducing a methyl group at the benzylic position (compound 2m, Scheme 4), or by C-1 homologation (compound 2n, Scheme 4).
In particular, as for the synthesis of 2l, 4-(p-fluorophenyl)-3,5-dimethyl pyrazole 10a was N-arylated with m-cyanophenyl boronic acid using copper(II) acetate; the resulting 1-(mcyanophenyl) pyrazole 12 was reduced to the corresponding benzylamine 2l with lithium aluminum hydride in unoptimized poor yields. Compound 2m was synthesized by reacting previously described 1-(p-cyanophenyl) pyrazole 6a with methylmagnesium bromide in reducing conditions. Finally, compound 2n was prepared from 4-(p-fluorophenyl)-3,5dimethyl pyrazole 10a, which was N-arylated with pcyanomethyl phenyl bromide according to a Buchwald− Hartwig reaction experimental protocol 26 (microwave reaction, aqueous K 2 CO 3 and DMSO, CuI, and L-proline, 140°C, 26 h). The resulting pyrazole intermediate 13 was then reduced with sodium borohydride in the presence of cobalt(II) chloride to obtain the corresponding target benzylamine 2n.
Compounds 2l, 2m, and 2n mostly maintained the activity of the early pyrazole lead 2a and showed high ASIC2a isoformselectivity (Table 2) , whereas the nitrile intermediate 6a was inactive, pointing out the relevance of a primary amine function for ASICs inhibition.
The "cyan" exploration was expanded by constraining the amine function within a 5-membered ring. To this aim, compounds 2o−r bearing a more symmetrical (2o, 2q) or unsymmetrical amine (2p, 2r), and a p-F (2o, 2p) or m-F substituent at the 4-phenyl ring (2q, 2r), were prepared. Their synthesis is reported in Scheme 5. Namely, previously 
a IC 50 were determined as described in the Supporting Information; they are expressed in μM and are the average value of at least n = 3 independent experiments ± SEM. 
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The resulting N-Boc-protected 4-(p-fluorophenyl) pyrazoles 14a and 15a were obtained in 42% and 15% unoptimized yields, respectively. Then, removal of the N-Boc protecting group in acidic conditions afforded the corresponding target compounds 2o and 2q in 32% and 63% yields, respectively. Intermediates 10a and 10b underwent the same coupling reaction with 6-bromo indoline, obtaining the corresponding target compounds 2p and 2r in 44% and 13% yields, respectively (Scheme 5).
The inhibition of ASICs constructs by "cyan" compounds 2o−r is reported in Table 2 . In particular, the isoindoline derivative 2o exhibited good in vitro activity and complete ASIC2a isoform selectivity. Conversely, compound 2q inhibited both ASIC2a and ASIC1a/2a isoforms (IC 50 = 9.9 and 11.3 μM, respectively). Notably, the corresponding indoline derivatives 2p and 2r were inactive.
Finally, the phenyl ring bearing the benzyl amine function was replaced ("green" exploration) by a 2-pyridine (2s) and a 3-pyridine (2t) ring, whereas dihydropyrrolo [3,4-d] pyrimidine homologues 2u and 2v and the N-Me derivative of the latter compound 2w were prepared. Their synthesis is depicted in Scheme 6.
Previously described 4-(p-fluorophenyl)-3,5-dimethyl pyrazole intermediate 10a was smoothly N-arylated with p-cyano-2-pyridyl fluoride in basic conditions (NaH in DMF); the resulting 1-(p-cyano-2-pyridyl) pyrazole 16 was reduced to the corresponding benzylamine derivative 2s with lithium aluminum hydride in unoptimized, poor yields. Instead, the corresponding m-F analogue 2t was synthesized from 10a and 5-bromo-2-cyanopyridine using Cs 2 CO 3 , CuI, and 1,2-cyclohexanediamine. This coupling reaction was run in a microwave reactor for 13 h at 120°C, and afforded cyano intermediate 17, which was then reduced to amine 2t in a poor, unoptimized 16% yield. Alternatively, compound 10a was N-arylated with tert-butyl 4-chloro-5,7-dihydro-6H-pyrrolo [3,4-d] pyrimidine-6carboxylate as seen earlier; the resulting N-Boc-protected pyrazole 18 was deprotected in acid conditions to yield the target compound 2u in poor, unoptimized yields. Then, intermediate 10b was transformed into the target compound 2v by N-arylation followed by removal of the Cl atom by hydrogenolysis to give intermediate 20, which was deprotected in acid conditions to the corresponding NH-free pyrazole 2v. Finally, this compound was N-methylated to yield compound 2w in good yields (Scheme 6).
As shown in Table 2 , none of the compounds 2s−w inhibited ASIC1a. The presence of a 2-pyridyl ring was well tolerated by ASIC2a (2s). Conversely, the presence of a 3pyridyl ring led to complete inactivity (2t). The dihydropyrrolo [3,4-d] pyrimidine derivative 2u was an ASIC2 inhibitor (IC 50 = 17.0 μM) selective against the ASIC1a/2a heterodimer. Surprisingly, its close congeners 2v and 2w, bearing a 4-(m-fluorophenyl) substitution, resulted to be completely inactive.
Compound 2a, 2o, and 2u were further profiled in terms of early physicochemical and ADME properties. In vivo PK characterization of 2u over 2o in mice was given priority, owing to its more drug-like physicochemical features (cLogP = 2.6 and 4.1; TPSA = 56 and 29 Å 2 for 2u and 2o, respectively). The summary of both the in vitro and in vivo characterization studies performed on 2a, 2o, and 2u is reported in Table 3 .
As for physicochemical descriptors, compound 2u was significantly less lipophilic than 2a and exhibited a greater TPSA value. Both compounds showed acceptable kinetic solubility and plasma protein binding (PPB). No inhibition of hERG was observed up to 30 μM concentration. In terms of inhibition of CYP450 isoforms, compound 2a was found to 
Letter inhibit two different isoforms, i.e., 1A2 and 2D6, although at different extents, whereas 2u inhibited only the 1A2 isoform. Particularly relevant were the differences observed in the in vivo pharmacokinetics in mice. Both compounds were tested at 1 mg/kg, i.v. and at 3 mg/kg, p.o. Notably, 2a was highly cleared following i.v. administration (Cl = 224 mL/min/kg) but widely distributed in tissues (Vd = 50.9 l/kg), resulting in a low C max after oral administration (C max = 0.09 μM). However, being highly brain penetrant (B/P = 61), a relevant total brain concentration was observed after the administration of 1 mg/ kg dose, i.v. (C max = 2.46 μM). Conversely, compound 2u showed a more balanced pharmacokinetic profile, owing to a sizable enhancement of the metabolic stability (Cl = 34 mL/ min/kg) with respect to compound 2a, an appropriate tissue distribution (Vd = 1.4 l/kg), complete absorption after oral administration (F = 100%) along with a significantly higher exposure p.o. with respect to 2a (C max= 2.6 μM), and good brain penetration (B/P = 1.3). The relevant improvement of pharmacokinetic profile of 2u vs 2a was most likely due to the lack of the basic, metabolically labile primary benzylamine function present in compound 2a, which was appropriately masked in 2u within the constrained dihydropyrrolo [3,4d] pyrimidine bicyclic moiety.
In conclusion, the described exploratory strategy enabled the identification of novel ASIC2 inhibitors. In particular, the "cyan" optimization approach focused on the stabilization of the terminal benzylamine function, which allowed to obtain compounds 2o and 2u, the selective ASIC2a-targeted in vivocompliant lead compound. This compound, owing to its relevant drug-like character and balanced pharmacokinetic profile (including brain penetration), may represent a valuable tool compound to validate p.o. the role of ASIC2 in vivo in animal models of different type of CNS pathologies. In addition, 2u can be seen as a foundation molecule for future optimization studies. 
